GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » PB Ratio

Viracta Therapeutics (STU:RYIS) PB Ratio : 4.89 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-27), Viracta Therapeutics's share price is €0.645. Viracta Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €0.13. Hence, Viracta Therapeutics's PB Ratio of today is 4.89.

The historical rank and industry rank for Viracta Therapeutics's PB Ratio or its related term are showing as below:

STU:RYIS' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 5.87
Current: 5.14

During the past 4 years, Viracta Therapeutics's highest PB Ratio was 5.87. The lowest was 0.00. And the median was 0.00.

STU:RYIS's PB Ratio is ranked worse than
77.02% of 1314 companies
in the Biotechnology industry
Industry Median: 2.525 vs STU:RYIS: 5.14

During the past 12 months, Viracta Therapeutics's average Book Value Per Share Growth Rate was -88.00% per year.

Back to Basics: PB Ratio


Viracta Therapeutics PB Ratio Historical Data

The historical data trend for Viracta Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics PB Ratio Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 1.32 0.83 1.64

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.53 1.63 1.64 7.39

Competitive Comparison of Viracta Therapeutics's PB Ratio

For the Biotechnology subindustry, Viracta Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viracta Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's PB Ratio falls into.



Viracta Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Viracta Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.645/0.132
=4.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Viracta Therapeutics  (STU:RYIS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Viracta Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viracta Therapeutics (STU:RYIS) Business Description

Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines